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http:CLINICAL VIGNETTE
A 66 year old man with progressive loss of kidney function is referred because he will need dialysis within a few
days. His radial artery is calciﬁed and the cephalic vein very small. Should one opt for an autologous arterio-
venous ﬁstula combined with a temporary central vein catheter with uncertain prognosis, or an early cannu-
lation AV prosthetic graft, thereby avoiding a central venous catheter?Background: Adequate functioning vascular access is the key to successful hemodialysis. The use of an
autologous arteriovenous ﬁstula (AVF) is advised because of good long-term patency and a low incidence of
complications. However, the number of patients with AVFs is declining because of the change in the demography
of the dialysis population, with increasing numbers of very old patients with multiple comorbidities.
Methods: In this vignette an elderly patient is described with calciﬁed distal arteries and a small cephalic vein
who is referred at a late stage for access creation. The results and performance of different types of vascular
access (AVF; arteriovenous graft; central vein catheter), in relation to late referral and patient demographics, are
described. In addition, patient morbidity and mortality versus the type of access are discussed.
Conclusions: The patient described in this vignette appears to be unsuitable for the creation of a forearm AVF
because of calciﬁed distal arteries and a small cephalic vein. The risk of non-maturing autologous AVFs is high in
elderly patients and this observation might justify the use of early stick grafts. High risk patients may beneﬁt from
permanent central vein catheters.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Arteriovenous graftTHE CLINICAL PROBLEM
Worldwide more than two million patients with end-stage
renal disease (ESRD) have renal replacement therapy (RRT)
by either renal transplantation, peritoneal dialysis (PD), or
intermittent hemodialysis (HD). The number of elderly (>65
years of age) patients on HD is growing more rapidly than
younger age groups. The associated comorbidities in elderly
patients (diabetes, arteriosclerosis) usually make vascular
access (VA) creation more difﬁcult.
Adequate functioning vascular access is the key factor for
successful HD treatment. Guidelines advise the creation and
use of autologous arteriovenous ﬁstulae (AVFs) for HD,
because of good long-term patency and a low incidence of
complications.1,2 The morbidity and mortality in patients
with AVFs is signiﬁcantly lower than in patients withresponding author. Department of Surgery, P Debijelaan 25, 6202
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//dx.doi.org/10.1016/j.ejvs.2015.02.006arteriovenous prosthetic grafts (AVGs) or central vein cath-
eters (CVCs).3 In addition, healthcare costs are considerably
lower with the use of AVFs than other access modalities.4
Despite the development of guidelines and better insight
into the process of vessel remodeling and maturation after
the creation of an arteriovenous anastomosis, the number
of HD patients with autologous AVFs is declining. The major
cause for this observation is the change in the demography
of the dialysis population with increasing numbers of very
old patients accepted for RRT, with multiple comorbidities
including obesity, chronic heart failure, diabetes mellitus,
peripheral vascular disease (PVD), and hypertension. Poor
vessel quality, previous vein punctures, and infusions
hamper the successful creation of autologous AVFs in these
patients. Other factors negatively inﬂuencing AVF outcome
are late referral for access creation and cannulation failure.LATE REFERRAL AND VASCULAR ACCESS CREATION AND
OUTCOME
An early referral to the vascular surgeon for vascular access
creation is pivotal for deciding on a patient-speciﬁc strategy
Preferred Strategy for Hemodialysis Access Creation 739for planning access. Guidelines advise referral at least 3e6
months before the expected start of HD, because time is
needed for AVF maturation and possible repeat in-
terventions when it is impaired. An early referral results in
more autologous AVFs, which have a better long-term
patency, whereas late referral results in a greater risk of
AVF non-maturation and failure and therefore the need for
additional CVCs to initiate dialysis.5 There is a great variety
with regard to timing of patient referral and access creation,
in particular between the United States and Europe. Plan-
ning for access surgery after referral varies from fewer than
5 days (Italy) to more than 42 days (UK).6 Streamlining
patients with better predialysis care and the implementa-
tion of vascular access coordinators may improve referral,
access planning, and outcome.7,8
A large study cohort of 17,511 patients> 67 years old, with
an AVF placed as the ﬁrst predialysis access, studied the
optimal time for AVF placement. AVF success was deﬁned as
dialysis initiation using the AVF, with time between AVF
placement and starting dialysis as the primary variable of
interest. Overall, 54.9% of patients initiated dialysis using an
AVF, and 45.1% used an AVG or CVC. An a priori time period
from AVF placement to HD initiation was set into ﬁve cate-
gories (1e3, 3e6, 6e9, 9e12, and >12 months) and the
success rate in each category was compared with a reference
time point of>12months from AVF creation to HD initiation.
The odds ratio (OR) for success increased as the time from
AVF creation to HD initiation increased in the categories of
1e3, 3e6, and 6e9 months (OR 0.49, 95% conﬁdence in-
terval [CI] 0.44e0.53; OR 0.93, 95% CI 0.85e1.02; and OR
0.99, 95% CI 0.88e1.11, respectively) but then stabilized.
Thus, placing an AVF > 6e9 months predialysis is not asso-
ciated with greater success. The number of additional inter-
ventional access procedures to enhance AVF maturation and
assisted primary patency increased over time starting at 1e3
months, with a mean of 0.64 procedures/patient for AVFs
created 6e9 months before HD start compared with 0.72 for
AVFs created 12 months before the start of HD (p > .001).
From this study one may conclude that referral 6 monthsFigure 1. Forest plot compares the odds ratio (95% conﬁdence interval)
elderly and non-elderly patients. The number before the slash refers to
total number of patients at risk. The solid central line represents no dif
bottom with a bold line.14before access creation might be ideal. With larger time in-
tervals, the incidence of access revisions will increase, which
is undesirable.9
Another study showed that the rate of renal deteriora-
tion may be of importance for the decision to create AVFs
at an early stage. A Markov model was used to compare
two strategies: refer all Stage 4 (glomerular ﬁltration
rate < 15 mL/min) ESRD patients for an AVF versus wait
until the patient starts dialysis. The wait strategy resulted in
a higher life expectancy (66.6 vs. 65.9 months) and quality
adjusted life expectancy (38.9 vs. 38.5 quality adjusted life
months) than immediate AVF creation. These results sug-
gest that despite the recommendation to consider creation
of AVF early in the pre-dialysis period, this may not apply to
all patients. It might be prudent to wait in patients who
have a slow rate of progression and high rates of competing
events. On the other hand, it is not optimal to wait in pa-
tients with a high rate of progression (such as proteinuric
diabetic nephropathy). The conclusion was that early crea-
tion of an AVF is not always the preferred strategy for all
predialysis patients.10
ACCESS FAILURE VERSUS LONG-TERM PATENCY AND
INTERVENTIONS
Pre-operative vessel assessment with ultrasonography re-
sults in signiﬁcantly more and better functioning autologous
AVFs. A randomized study showed an obvious difference
between the early failure rate and long-term patency of
radiocephalic AVFs in patients assessed with ultrasound
versus clinical examination alone.11 A meta analysis showed
that certain patients may beneﬁt from pre-operative ultra-
sonography in terms of more and better functioning
autologous AVFs.12 There remains a debate about the
acceptable lower limits of arterial and venous vessel di-
ameters and the presence of calciﬁcation in relation to the
chance of successful maturation. Arterial calciﬁcation im-
pairs outward remodeling of the inﬂow artery and thus
hampers the ﬂow increase and resulting arterial and venous
dilatation. Calciﬁcation in the forearm arteries detected onof the primary failure rate of radiocephalic arteriovenous ﬁstula in
the number of failures, and the number after the slash refers to the
ference in the odds ratio. The pooled effect is demonstrated at the
Figure 3. KaplaneMeier survival curves for all cause mortality for
the whole cohort (A) (n ¼ 3381) and the propensity score matched
cohort (B) (n ¼ 1479) for patients with arteriovenous ﬁstula versus
central vein catheter.17
740 J.H.M. Tordoir et al.a plain arm radiograph is predictive of a poor outcome of
radiocephalic AVFs in diabetic patients. The primary and
secondary patency rates after 12 months are signiﬁcantly
lower than in diabetic patients with non-calciﬁed arteries
(primary patency 50% vs. 72% and secondary patency 52%
vs. 78%). In addition, patient survival is 56% versus 92%
after 2 years of follow up. The conclusion was that the long-
term beneﬁt of radiocephalic AVFs may be lost in diabetics
with extensively calciﬁed vessels, and that the brachial ar-
tery should be used preferentially instead.13
This recommendation to use brachial artery-based AVFs
was investigated in a meta-analysis comparing the forearm
AVF failure rate in non-elderly versus elderly patients (>65
years), and the use of brachiocephalic AVF and AVGs. The
primary radiocephalic AVF failure rate was signiﬁcantly
lower in the non-elderly patients (OR 1.79; p > .012). Long-
term follow up also revealed a signiﬁcantly better overall
AVF patency rate in younger patients than in elderly pa-
tients at 12 (OR 1.525, p > .001) and 24 months (OR 1.357,
p > .019; Fig. 1). Secondary analysis revealed a pooled ef-
fect in favor of the brachiocephalic AVF that was statistically
signiﬁcant (p > .004) compared with radiocephalic AVFs in
elderly patients. No differences in the outcome of forearm
AVF and AVG in elderly patients were found (Fig. 2).14
Caution should be exercised in the use of the brachial
artery for AVF inﬂow in diabetic patients with calciﬁed ar-
teries, because the probability of access related peripheral
ischemia increases signiﬁcantly.15,16
ACCESS TYPE VERSUS MORTALITY AND MORBIDITY
AVFs are the preferred vascular access in most patients
because of their longevity, lower rates of infection, in-
terventions, and better patient survival. In a large cohort of
patients, propensity scores for death were used both as
variables in the multivariate model and to construct
matched cohorts. There were 612 deaths in 3749 patients.
After adjustment for confounding factors and propensity
scores, CVC use was the single predictive factor for mor-
tality. All cause mortality rates in this cohort were 115 perFigure 2. Forest plot compares the risk difference (95% conﬁdence int
ﬁstula versus arteriovenous graft in elderly patients. The solid central li
at the bottom with the bold line. The number before the slash refers to
total number of patients.141000 patient years (95% CI 94e142 deaths) in patients with
an AVF and 242 per 1000 patient years (95% CI 211e277
deaths) in patients with a CVC. Patients with AVGs also had
a signiﬁcantly increased risk of death compared with pa-
tients with AVFs. However, given the small numbers of
grafts, all conﬁdence intervals remained non-signiﬁcant
(Figs. 3 and 4).17
For many patients initiating hemodialysis with a CVC,
attempting to place an AVF is a reasonable strategy,
although it may not be ideal for all patients, and AVFerval) of the 12 month failure rate of radiocephalic arteriovenous
ne represents no risk difference. The pooled effect is demonstrated
the number of failures and the number after the slash refers to the
Figure 4. KaplaneMeier survival curves for all cause mortality for
the whole cohort (A) (n ¼ 2632) and the propensity score matched
cohort (B) (n ¼ 637) for patients with arteriovenous ﬁstula versus
arteriovenous graft.17
Figure 5. Patient survival by access attempt strategy. Plots are stratiﬁed
the patients. The y axis represents the survival in years. Patient s
AVF ¼ arteriovenous ﬁstula; AVG ¼ arteriovenous graft.
Preferred Strategy for Hemodialysis Access Creation 741creation may be applicable for younger patients in partic-
ular. In older patients, including female and/or diabetic
patients, no mortality difference among the three vascular
access types is found (Fig. 5). Age, sex, and diabetes are
predictors of both the probability of AVF failure and overall
mortality.18PATIENT FACTORS VERSUS ACCESS PERFORMANCE
Optimal selection of an AVF versus an AVG requires careful
consideration of the tradeoffs. Once they are successfully
cannulated for dialysis, AVFs clearly enjoy longer survival
than AVGs and require fewer interventions to maintain
patency. The advantages are counterbalanced by the pro-
portion of AVFs that do not mature and are not suitable for
dialysis, as well as the longer time to ﬁrst cannulation. In
patients who have already initiated dialysis, this translates
into prolonged CVC dependence. Trilaminar prosthetic
grafts that are suitable for early cannulation within 24 h of
insertion may obviate the need for placement of temporary
CVCs, and can be indicated for selected patients.19 The
REDUCE (Risk Equation Determining Unsuccessful Cannula-
tion Events) study identiﬁed pre-operative clinical charac-
teristics that are predictive of AVF failure and used these
predictive factors to develop a scoring system to stratify the
patient’s risk of failure (Table 1). The clinical predictors that
were associated with AVF failure in a group of 422 patients
who had a ﬁrst AVF created were; age >65 year (OR 2.23,
95% CI 1.25e3.96, p < .01), PVD (OR 2.97, 95% CI 1.34e
6.57, p < .01), coronary artery disease (OR 2.83, 95% CIby sex and diabetes status. The x axis represents the age in years of
urvival in years by age stratiﬁed by sex and diabetes status.18
Table 1. Clinical use of the scoring system.20
Variable Points score Variable deﬁnitions
Age > 65 yrs þ2 Age at time of ﬁstula creation
PVD þ3 Documented lower extremity revascularization, digit or extremity amputation, history of
claudication and ischemic extremity changes or gangrene
CAD þ2.5 Documented coronary stenosis by angiography or history of myocardial infarction or previous
coronary revascularization by angioplasty, stenting, or bypass surgery
White 3 Not of black, Asian, aboriginal, or other non-European descent
Baseline score þ3 All patients are given baseline score of 3
Total Sum of scores
The total score could range from 0 to 10.5.
Figure 6. The percentage of AVF failure to mature in each risk
category were: low risk, 24%; moderate risk, 34%; high risk, 50%;
and very high risk, 69% (p > .0001).20
742 J.H.M. Tordoir et al.1.60e5.00, p < .01), and white race (OR 0.43, 95% CI 0.24e
0.75, p < .003). The risk categories varied from <2 (low),
2e3 (moderate), 3.1e7.9 (high), and very high (>8.0
points). For instance, age >65 years (2 points), peripheral
vascular disease (3 points), and white race (3 points) add
to the total score of the individual. This scoring system was
validated in another 445 patients, and showed AVF non-
maturation in 24% of patients with a low score, 34% in
patients with a moderate risk score, 50% in patient with
high risk scores, and 69% AVF failure in very high risk pa-
tients. A pre-operative, clinical prediction rule to determineFigure 7. An algorithmic guide to choosing appropriate vascular access
important clinical factors: timing of access surgery relative to initiatio
vascular access. This information, along with the likelihood of arteriove
vascular access: ﬁstula (F) or graft (G).21ﬁstulae that are likely to fail maturation was created and
validated.20 It was found to be simple and easily repro-
ducible and applied to predictive risk categories (Fig. 6).
On the basis of the expected survival of the patient, the
need for urgent HD, and a history of previous failed vascular
access, combined with the scoring system as determined in
the REDUCE study, an algorithm has been proposed on
which the strategy for choosing AVF versus AVG can be
selected (Fig. 7).21
RECOMMENDATIONS
The patient described in this particular vignette appears to
be unsuitable for the creation of a forearm AVF, because of
calciﬁed distal arteries and a small cephalic vein (age > 65
years and calciﬁed arteries ¼ 5 points; AVF non-maturation
risk ¼ 50% [Table 1; Fig. 6]). A brachiobasilic AVF might be
possible depending on the outcome of the pre-operative
vessel assessment. If successful, brachiobasilic AVFs need
at least 6 weeks for maturation before cannulation can be
initiated and therefore the need for a temporary CVC re-
mains. In addition, the risk of ischemic steal with brachial
artery-based AVFs may be substantial.
Chronic HD through a CVC is an alternative short-term
solution, but carries a 15e27% higher mortality rate. For
very old patients with a limited life expectance, CVC dialysis
may be an acceptable option, but such a strategy is not
suitable for a 66 year old patient. Early cannulation AVGs
can be the ultimate solution to start HD in a few days,for intermittent hemodialysis patients. This protocol requires three
n of hemodialysis, life expectancy of the patient, and prior failed
nous ﬁstula maturation, is used to determine the most appropriate
Preferred Strategy for Hemodialysis Access Creation 743thereby avoiding the use of a CVC and its devastating
complications. AVGs have similar mortality rates to AVFs in
diabetic patients, but at the cost of a greater number of
interventions to maintain patency.
The risk of non-maturing autologous AVFs is high in
elderly patients and this observation might justify the use of
early stick grafts. Younger patients with acceptable risk
factors should preferentially receive AVFs, when needed,
bridged by a temporary CVC.
Lastly, high risk patients, for instance elderly diabetic
women, may beneﬁt from permanent CVCs as the HD ac-
cess of choice.
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